City Research Online

Abstract

More than 100,000 people have participated in controlled trials of statins (lowering cholesterol drugs) since the introduction of lovastatin in the 80s. Meta-analyses of this data have shown that statins have a beneficial effect on treated groups compared to control groups, reducing cardiovascular risk. Inhibiting the HMG-CoA reductase in the liver, statins can reduce cholesterol levels, thus reducing LDL levels in circulation. Published data from intravascular ultrasound studies (IVUS) was used in this work to develop and validate a unique integrative system model; this consisted on analysing control groups from two randomised controlled statins trials (24/97 subjects respectively), one treated group (40 subjects, simvastatin trial) and 27 male subjects (simvastatin, pharmacokinetic study). The model allows to simulate the pharmacokinetics of statins and its effect on the dynamics of lipoproteins (e.g. LDL) and the inflammatory pathway whilst simultaneously exploring the effect of flow-related variables (e.g. wall shear stress) on atherosclerosis progression.

Publication Type:	Article
Additional Information:	© 2014 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Subjects:	Q Science > QA Mathematics > QA75 Electronic computers. Computer science R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Departments:	Presidents's Portfolio
SWORD Depositor:	Symplectic Administrator

Export

Downloads